Contraction/conduction and cardiac glycosides Flashcards

1
Q

Contractility

A
  • Force of contraction
  • Increase preload=Increase contractility
  • Decrease afterload=Increase contractility
  • Contractility is independent of loading
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

SV factors

A
  • Contractility
  • Preload
  • Afterload
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Fast AP

A
  • aka muscle/Long AP
  • Ventricular Myocyte
  • His-Purkinje System, Atrial and ventricular muscle
  • Mediated by Na+ influx
  • Resting membrane potential is lower than nodal
    • prevents hyperexcitabilty
    • wont spontaneously fire
    • wait for signal from nodal tissue
  • Phase 0,1,2=QRS
  • Phase 3=T wave
  • Phase:
    • Phase 0=depolariation
      • Na+ Channel opens, Na+ influx
      • Upstroke; Increase permeability of Na+
    • Phase 1: partial repolarization
      • Na+ Channel closes, K+ channel opens
      • K+ eflux
    • Phase 2: Plateau phase=K+-mediated
      • Ca2+ Channel opens, (Fast K+ Channel close)
      • Ca2+ Influx (K+ efflux)
    • Phase 3: Ca2+ Channel close, Slow K+ channel open
      • K+ efflux
    • Phase 4: Resting potential
      • stable potential; K+ eflux
  • Class I and III antiarrhythmics
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Fast AP:Absolute refractory period

A
  • aka effective refractory period
  • Under no circumstance will heart fire/depolarize
  • phase 0-2 of Fast AP
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Fast AP: Relative Refractory Period:

A
  • Mostly refractory but if you come in w/a strong enough stimulus=you can trigger a resopnse
  • PHASE 3
  • Problem: Long QT Syndromes
    • arrival of T wave is delayed (repolarization delayed)
    • common source for dangerous arrhythmias
    • occurs due to dysfunctional K+ channels
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Cardiac Glycosides: Pharmocological effects:

A
  • Improves contractility
    • Increase CO
    • Increase Renal BF
    • Decrease Blood Volume and edema
    • Decrease preload
  • Sensitize the carotide sinus (Both causes Decrease HR)
    • Decrease Sympathetic tone
    • Increase Vagus tone
  • Vasodilation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Cardiac Glycosides: MOA:

A
  • Inhibition of Na+/K+ ATPase causes Increase in intracellular Na+
  • 2 possible mechanisms
  1. Inhibits Ca2+/Na+ exchange–>Less Ca2+ extrusion–> Increase Ca2+ intracellular
  2. Stimulates Ca2+/Na+ exchanger–> Na+ eflux, Ca2+ influx
  • Both Cause Increase of Ca2+ intracellular–>Stimulates Contractile proteins
  • Increase Force of contraction (contractility)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Cardiac Glycosides: Electrical effects

A
  • Inhibition of pump redistributes Na+, Ca2+, and K+
    • Depolarizes Cells
  • Increase ectopic automaticityin heart
    • due to Ca2+ Loading
  • Increase refractory period early
  • Decrease conduction velocity due to increase vagal tone
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Effects of Digoxin on electrical properties of cardiac tissue: SA Node etc:

Therapeutic dose vs toxic doses

A
  • SA Node
    • Therapeutic: Decrease rate
    • Toxic: Decrease rate
  • Atrial Muscle
    • Therapeutic:
      • Decrease refractory period
    • Toxic:
      • Decrease refractory period
      • arrhythmias
  • AV node:
    • Therapeutic:
      • Decrease conduction velocity
      • Increase refractory period
    • Toxic:
      • Decrease refractory period
  • His-purkinje/ Ventricles:
    • Therapeutic:
      • Slight decrease refractory period
    • Toxic:
      • extrasystoles
      • tachycardia
      • Fibrillation
  • ECG:
    • Therapeutic:
      • Increase PR interval
      • Decrease QT interval
    • Toxic:
      • Tachycardia
      • Fibrillation
      • Cardiac arrest with really high doses
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Digoxin: Pharmokinetics:

Onset, optimal serum levels, GI Absorption, Plasma half life, Daily excretion, Plasma protein, excretion

A
  • Onset of action: 10-30 mins
  • Optimal serum levels:
    • 0.5-2.5ng/mL
  • GI Absorption:
    • Tablets: 60-80%
    • Lanoxicaps: 90-100%
  • Plasma Half Life
    • 35-40 hours
      • Load dose
  • Daily excretion:
    • 30%
    • kidney disease=modify dose
  • Plasma protein Binding:
    • 20-40% excreted out
  • Excretion:
    • kidney
    • CCR=Creatine clearance level: Assess in elderly to determine if you need to modify dose
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Digoxin: Toxicities:

A
  • High Risk of Toxicity:
    • 20-25% hospitalized patients
  • Greater risk in advanced heart disease
  • Antidote for Overdose:
    • Digoxin immune fab
  • Cardiac Toxicities:
    • Primary toxic effect is arrythmias
      • can be sinus block, AV block, AV junctional arrythmias
      • casues:
        • premature ventricular contractions (most common)
        • Tachycardia
        • Ventricular Fibrillation
  • Non-cardiac toxicities
    • Fatigue, muscles weakness
    • GI
      • Anorexia
      • Nausea-cenrally mediated
        • common early sign
    • CNS:
      • difficulty walking
      • confusion
      • halucinations
      • restlessness
      • insomnia
      • drowsiness
      • Psychoses
    • Vision:
      • blurred
      • photophobia
      • alterations in color=objects appear green or yellow
    • some make pats develop gynectomastia
      • due to androgenic effect
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Digoxin: Factors that increase conc.

A
  • High dose (received wrong dose)
  • Reduced renal fxn
    • decreased excretion
  • Altered distribution
    • elderly-lean body mass
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Digoxin: DDIs

A
  • Diuretics–>produce hypokalemia
    • decrease Plasma K+ and Mg2+
    • Increase serum Ca2+
    • Increase Toxicity
  • Antacids: Decrease absorption
    • Decrease K+
  • Corticosteroids:
    • decrease serum K+
    • Increase toxicity
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What maintains Resting membrane potential in fast action potentials?

A
  • K+ Leak channels
  • Na+/K+ ATPase
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Mechanism of Fast APs

A
  1. Nodal AP enters from adjacent cell
  2. Voltage gaded Ca2+ channels open, Ca2+ enters
  3. Ca2+ induces Ca2+ release through ryanodine receptor channels (RYR) from sarcoplasmic reticulum
  4. Local release causes Ca2+ spark
  5. Summed Ca2+ spark creates a Ca2+ signal
  6. Ca2+ ions bind to troponin to initiate contraction
  7. Relaxation occurs when Ca2+ Unbinds from Troponin
  8. Ca2+ is pumped back into sacroplasmic reticulum to storage
  9. Ca2+ is exchanged with Na+
  10. Na+ gradient is mainted by the Na+/K+ ATPase
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

How do we regulate force of contraction in the heart and steps:

A

Sympathetic stimulation (Increase Contractility and HR)

  • B-adrenergic stimulation leads to: (NE binds)
    • phosphorylationof membrane Ca2+ channels causes them to be more open–>increasing transmembrane Ca2+ influx
    • Phosphorylation of Troponin-1 inhibits Ca2+ binding to troponin-C, making it easier to remove Ca2+ from binding sites
      • Increase Ca2+ turnover into contractile proteins
    • Phosphorylation of Phospholamban, which removes inhibitiory control on sarcoplasmic reiculum ATPase, and increase Ca2+ uptake into SR
    • NET Result:
      • increased force of contraciton
      • decreased contraction time caused by increase rate of contraciton and rate of relaxation
  • Cardiac Glycosides=downside
    • inhibit Na+/K+ pump which results accumulation of Na+ intracellular is it effects all Na+/K+ ATPase pumps thorughout the body which can cause hyperkalemia
      • Na+ Intracellular Increase
      • Ca2+ intracellular increase
      • K+ Extracellular increase (hyperkalemia)
      • Increase contractility
17
Q

Control of BP

A
  • Cardiovascular system:
    • Cardiac Output:
      • Preload
      • contractility
      • Afterload
      • HR
  • Vascular
    • Vascular Resistance
      • sympathetic tone
      • Autoregulatory factors
  • Kidneys: Long term
    • fluid volume regulated by renal control
18
Q

How to figure out preload from system

A
  • Preload
    • preload=filling of the heart during diastole
      • Increase Preload=Increase Contractility
    • EDV: End Diastolic Volume
      • best indicator for how full the heart is before contraciton
      • most accurate but hard to measure=need cardiac ultrasound
    • EDP: End Diastolic pressure
      • measured by ventricular cather
      • tells us what preload is
    • CVP-Central Venous Pressure
      • most common to assess preload
      • Equilibrates with the ventricle
      • By the end of diastolic filling, the EDP=CVP
      • no catheter needed
      • Look for jugular vneous distention, bc close to inferior vena cava=reflect CVP
      • How much distention you see give you how high CVP is:
        • How high above the clavicular line you see the jugular vein OR
        • how high pulse in jugular vein
      • used to determine whether your heart is capable of moving the fluid
      • Incrrease CVP=HF
19
Q

What can make Central Venous Pressure increase?

20
Q

Contractility:Performance measures of the system

A
  • SV-need cardiac ultrasound
  • CO-need cardiac ultrasound
  • SBP-systolic Blood pressure
    • pulse amplitude (pulse pressure)=SV
    • Pulse pressure=SBP-DBP
    • Increase PP=Increase SV
  • EF: Ejection fraction
    • radiograph image or ultrasound
    • What % of starting EDV (end diastolic volume) Was ejected
    • EF= SV/EDV
    • normal: 50-60%; decreases in sick hearts
    • used most common
21
Q

Afterload of system to determine contractiility:

A
  • Afterload=Resistance
    • DBP=diastolic blood pressure
      • best indicator for resistance
      • Increase TPR=Increase Afterload
22
Q

Starling law of Heart

A

How to evaluatae contractility

  • Starling curves=loading @ constant contractilty/afterload
  • relationship b/w preload and force
    • Increased EDV (Stretch) should increase the force being produced (contractility)=Increase SV
  • Normal resting values:
    • Force: indicated by SV
      • 70mL
    • Stretch=indicated byEDV
      • 135mL
  • Increase filling(preload)–> Increase performance (Force)
  • Indices of preload (x-axis)
    • EDV
    • EDP
    • CVP
  • Indices of performance (Y-axis)
    • SV
    • LVSP
    • CO
23
Q

Diuretics:

A
  • casues body to lose water (decrease blood volume) and urinate more
  • most common for BP control:
    • Thiazide diuretics: (Thiazides)
      • first line
      • long term use shows decreased reactivity of vessels
    • Looop Diuretics:
      • Furosemide
      • Congestive Heart Failure
    • Potassium Sparing diuretics
      • 3rd line w/BP control
24
Q

Drugs that interrupts the RAAS

A

really effective when plasma renin activity is high

  • Angiotensin-Converting Enzyme Inhibitors
    • ACE inhibitors
  • Angiotensin Receptor BLockers (ARBs)
  • Direct Renin Inhibitor:
    • Aliskerin
  • Aldosterone Antagonist
25
ACE inhibitors: - suffix - admin - metabolism - Side effects - DDIs - miscellaneous
* -pril * inhibits ACE * Admin: Oral * except enalaprilat * don't have to have food in system when you take * Metabolism: * excreted renally * Advise to take at night before bed to reduce risk of hypotension and maximize effictiveness * Side effects: * **COUGH** * iron supplement dampens this effect * Angioneurotic edema * more common in african americans * Hyperkalemia * applies to B-blockers, ARBS, DRIs * Acute renal failure in the presence of renal artery stenosis * Skin rash; abnormal taste sensation (iron) * Fetal harm due to exposre to ace inhibitors during 1st trimester * Never use any of the RAAS inhibitors * DDIs: * Diuretics * potassium sparing diuretics * Potassium supplements * Lithium * ACEI can raise lithium levels * NSAIDS * can inhibit antiHTN effects by retention of salt and water * Additional Benefits: * slow the progression of: * diabetes-induced nephropathy (proeinuria\>300mg/day) * diabetes-induced retinopathy _independent of BP lowering bc:_ * _​_Diabetes causes Increased VEGF * Angiotensin II interacts with VEGF=retinopathy
26
Current recommendations for RAAS drug prescription
* ACEIs and ARBS are the drugs of choice to prevent long-term cardiac remodeling * Use DRIs if side effects are not tolerated
27
ARBS: - suffix - MOA - admin - metabolism - Side effects - DDIs - miscellaneous
* -sartan/artan * MOA: * Angiotensin Type 1 antagonists (AT1 antagonists) * Blocks AT1 receptor * works similar to ACEI but: * ACEIs are decreasing Ang II * Block AT1 receptor where Ang II would bind * Downstream effects: * dilation of arterioles and veins * reduce excretion of K+ * decrease release of aldosterone * Increase renal excreetion of Na+ and Water follows * Do not inhibit ACE * DO not increase levels of Bradykinin * Side effects: * **NO COUGH-biggest advantage over ACEIs** * same as ACEIs * DDIs: * Same as ACEIs * **Losartan (Cozaar**
28
DRIs
Direct Renin Inhibitor=Aliskerin * Admin: Oral * MOA: Binds to the active site on renin * No cough * angioedema * NOT 1st line agent * Newer drug and more expensive * use if patient has side effects with angioedema from ARBs & ACEIs
29
Calcium Channel Blockers (CCBs)
* Aka Calcium channel antagonists * Slow calcium blockers * Calcium entry blockers * Calcium channels * critical role in the function of vascular smooth muscle and heart * 2 main groups * Nodihydropyridines: Verapamil & Diltiazem * acts on both VSM and heart * Dihydropyridines: Nifedipine * act on VSM only * MOA: * prevent calcium ions from entering the cell * greatest effect on heart and blood vessels * effective in low renin HTN * Physiologic fxns and consequences of blockade * VSM * regulate contraction= Decrease sensitivity of constriciton of vessels * CCBs act selectively on arterioles and arters, and arterioles of heart * no significant effect on veins * Heart: * Myocadrium: Ca2+ increases Contractility * inotropy * SA node: Decrease HR * AV node: decrease velocity of conduction * coupling Calcium channels to Beta1-adrenergic receptors * when B1 is activated, calcium influx is increased * Adverse effects: * **Constipation** * dizziness * facial flusing * headache * edema of ankles and feet * heart block-can report a heart attack on ECG * DDI: * Beta-adrenergic blocking agents * synergistic effect * Food * grape fruit juice (anything citrisy) * CYP3A4 * Digoxin * Toxicity: * severe hypotension * Bradycardia and AV block * Ventricular tachydysrhytmias=Fatal heart syndrome
30
Similarity b/w CCBs and Beta-Blockers
Have same effects: * Reduce force of contraction * slow HR * suppress conduction through AV node **DO NOT GIVE IN COMBO=SYNERGISTIC EFFECT** **-can introduce new arrythmias**
31
Nondihydropyridines:
* Type of CCB * Verapamil & Diltizaem * Admin: * oral or IV * Metabolism: Extensive 1st pass metabolism * MOA-act on VSM and heart * blacks Ca2+ channels * Both drugs act like one another=hemodynamic effects * vasodilation * reduced arterial pressure * increased coronary perfusion * Major therapeutic uses * angina pectoralis * essential HTN * cardiac dysrhythmias
32
Dihydropyridines:
Type of CCB * Nifedipine/Amlodipine * -dipine * MOA: Acts on VSM * Blocks Ca2+ channels * Hemodynamic effect * lowers BP * increases HR and contractile force * Therapeutic use: * angina pectoralis * HTN * relieve migraine headache * suppress preterm labor * Adverse effects: * **gingival hyperplasia** * **reflex tachycardia** * DDI * Beta-adernergic blockers (Beta blockers) * **often combined with beta-blocker to reduce** **reflex tachycardia** * **Long-acting Nifedipine reduces reflex tachycardia and is more useful in treating essential HTN than original short-acting**
33
Antihypertensive drugs: SNS target in CNS
* Primarily target the alpha 2 receptors (Adrenergic 2) in the CNS * inhibit SNS * CNS receptors: * B1 (Beta 1) * increases SNS activity=vasoconstriction * alpha 2 (a2) * inhibits SNS activity=vasodilation * Outcome: * reduciton in postganglionic nerve activity (NE) and adrenal medulla (NE/E) * leads to a reduction in vascular resistance (BP * Positive and Negative Feedback control of NE release @ sympathetic nerve termina * NE binds A2 and inhibits teh SNS * Negative feedback * NE binds to Beta receptors=Increase SNS activity * positive feedback
34
35
Beta-Adrenoreceptor Blockers
Aka Beta Blockers * -olol * Slows HR and Lowers BP * MOA: Block B1 adrenoreceptor (B1 receptor antagonist) * Heart=Reduce CO and HR * Kidney (B1)=reduced renin * CNS: inhibits SNS * BLood Vessels: Enhance endothelial synthesis of DGI2 * Adverse effects: * Adverse lipid profile * can mask or induce diabetes * Hyperglycemia * can mask or induce diabetes * Excessive bradycardia (such as AV block), arrythmyia * combo with CCBs * Hyperkalemia * Fatigue, depression, insomnia, CNS effects * Contraindications: * Asthma * don't use non-cardioselective B-Blcokers * can use cardioselective-hopefully only selects B1 * Diabetes * Peripheral artery disease-challenged by Nebivolol/metoprolol * DDIs: * NSAIDs * K-sparing diuretics * CCBs--\> nonodihydropyridine * can use with Nifediipine * Reasons: * reduced hypotensive actions=inhibits PGI2 produciton * Hyperkalemia * bradycardia * AV block
36
Slow AP
* SA node